ImmunoGen Signs Partnership with Vertex for Conditioning Agents worth US$352 M
By Swati Sharan
Pharma Deals Review: Vol 2023 Issue 3 (Table of Contents)
Published: 28 Mar-2023
DOI: 10.3833/pdr.v2023.i3.2774 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a bid to broaden its gene editing capabilities, Vertex Pharmaceuticals has entered into a global multi-target license and option agreement with ImmunoGen to leverage the latter’s antibody-drug conjugate (ADC) technology to discover targeted conditioning agents for use with gene editing...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS